TOP TIERMARKET NEWSWIRE

News & sentiment

REGENXBIO INC (RGNX) — News & AI sentiment

REGENXBIO INC (RGNX) news roundup. 1 story in the past week, 13 over 30 days. Average 30-day sentiment is 57.8/100. Recent insider activity (SEC Form 4, 90-day window): 1 purchases totalling $949K and 0 sales totalling $0 — net buying of $949K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

1

avg sentiment 56/100

30d stories

13

avg sentiment 57.8/100

Insider net (90d)

$949K

1 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

RGNX news in the last 24 hours, 7 days, 30 days and 90 days

How much RGNX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	RGNX stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	1	56/100	RGNX headlines →
Last 30 days	13	57.8/100	RGNX headlines →
Last 90 days	66	50.1/100	RGNX headlines →

Latest stories on RGNX

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases - Slideshow

Seeking Alpha56 · neutralproduct/pr

6d ago

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

Seeking Alpha58 · neutralproduct/pr

Oct 21

REGENXBIO Inc. (RGNX) files 8-K

SEC 8-K50 · neutralgeneral

Oct 16

ReGen III Announces Receipt of Complaint

StockTitan34 · bearishgeneral

Oct 15

REGENXBIO sets October 20 investor event ahead of sura-vec wet AMD pivotal topline data expected in 4Q 2026 October 13, 2026

MarketChameleon58 · neutralproduct/pr

Oct 13

Global Capsid Tropism Screening Platforms Market Report 2026 | Capitalize on 14.4% CAGR to $1.45B by 2030 as Sarepta, Voyager, REGENXBIO and Dyno Scale AI and NGS Screening

GlobeNewswire58 · neutralgeneral

Oct 12

RGNX schedules Oct. 20 investor event ahead of pivotal wet AMD topline data expected in 4Q 2026 October 12, 2026

MarketChameleon58 · neutralproduct/pr

Oct 12

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

PR Newswire58 · neutralproduct/pr

Oct 12

Regenxbio a new Outperform at Mizuho on potential of two pipeline drugs

Seeking Alpha67 · bullishanalyst

Oct 5

Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call

Stocktwits News73 · bullishanalyst

Oct 5

Mizuho initiates Regenxbio stock coverage with outperform rating

Investing.com Analyst Ratings61 · neutralanalyst

Oct 5

Regenxbio initiated with an Outperform at Mizuho

The Fly63 · neutralanalyst

Oct 5

Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist

Stocktwits News58 · neutralproduct/pr

Oct 5

H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data

Investing.com Analyst Ratings56 · neutralanalyst

Sep 28

Stifel reiterates Regenxbio stock rating on gene therapy data

Investing.com Analyst Ratings56 · neutralanalyst

Sep 25

Regenxbio stock gains on positive gene therapy trial data

Investing.com Markets71 · bullishproduct/pr

Sep 25

Regenxbio presents positive 3-year durability data for Surabgene Lomparvove

The Fly73 · bullishproduct/pr

Sep 25

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

PR Newswire73 · bullishproduct/pr

Sep 24

Sarepta Therapeutics, Inc.: Entered Settlement Agreement With Regenxbio, UPenn Trustees, and Catalent >SRPT

MarketWatch56 · neutralgeneral

Sep 23

REGENXBIO Inc. (RGNX) files 8-K

SEC 8-K50 · neutralgeneral

Sep 23

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

Sep 16

Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research

Barchart58 · neutralgeneral

Sep 12

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire56 · neutralgeneral

Sep 8

Regenxbio rises on new director stock purchase

Seeking Alpha58 · neutralgeneral

Aug 28

Regenxbio stock surges on director share purchases

Investing.com Markets63 · neutralgeneral

Aug 28

Open RGNX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →